Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 03, 2022

BUY
$0.69 - $1.21 $96 - $169
140 New
140 $0
Q1 2022

May 02, 2022

SELL
$1.02 - $3.8 $392 - $1,463
-385 Closed
0 $0
Q4 2021

Feb 23, 2022

SELL
$3.26 - $4.66 $145,826 - $208,451
-44,732 Reduced 99.15%
385 $1,000
Q3 2021

Oct 28, 2021

SELL
$4.08 - $5.66 $983 - $1,364
-241 Reduced 0.53%
45,117 $255,000
Q2 2021

Aug 12, 2021

BUY
$5.01 - $7.48 $111,743 - $166,833
22,304 Added 96.75%
45,358 $247,000
Q1 2021

Apr 26, 2021

BUY
$7.19 - $14.95 $148,430 - $308,627
20,644 Added 856.6%
23,054 $172,000
Q4 2020

Feb 02, 2021

BUY
$6.66 - $14.66 $15,471 - $34,055
2,323 Added 2670.11%
2,410 $26,000
Q3 2020

Oct 14, 2020

BUY
$8.69 - $14.47 $756 - $1,258
87 New
87 $0
Q4 2019

Feb 05, 2020

SELL
$4.52 - $10.1 $2,621 - $5,858
-580 Closed
0 $0
Q3 2019

Oct 15, 2019

SELL
$7.14 - $11.65 $928 - $1,514
-130 Reduced 18.31%
580 $6,000
Q2 2019

Jul 26, 2019

BUY
$5.5 - $9.75 $1,050 - $1,862
191 Added 36.8%
710 $6,000
Q1 2019

Apr 18, 2019

SELL
$5.51 - $9.59 $3,024 - $5,264
-549 Reduced 51.4%
519 $0
Q4 2018

Jan 16, 2019

SELL
$5.55 - $11.34 $2,713 - $5,545
-489 Reduced 31.41%
1,068 $5,000
Q3 2018

Oct 23, 2018

BUY
$9.74 - $12.92 $6,145 - $8,152
631 Added 68.14%
1,557 $18,000
Q2 2018

Jul 30, 2018

SELL
$10.16 - $13.65 $15,473 - $20,788
-1,523 Reduced 62.19%
926 $9,000
Q1 2018

Apr 26, 2018

SELL
$9.47 - $12.98 $88,904 - $121,856
-9,388 Reduced 79.31%
2,449 $31,000
Q4 2017

Jan 10, 2018

BUY
$8.45 - $17.48 $100,022 - $206,910
11,837
11,837 $115,000

About Syros Pharmaceuticals, Inc.


  • Ticker SYRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,236,200
  • Market Cap $43.1M
  • Description
  • Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...
More about SYRS
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.